Table 2.

Frequency of mutations and estimated risk of EOC in candidate genes for validation chip genotyping data

Set*	Histotype	Gene	Controls		Cases		OR (95% CI)	P value
			No.	%	No.	%
OCAC	Overall	PALB2	6	0.03	11	0.08	2.10 (0.74 to 5.94)	0.16
		Non-carrier	18 930	99.97	13 277	99.9
	HGSOC	PALB2	6	0.03	6	0.097	3.48 (1.10 to 11.1)	0.035
		Non-carrier	18 930	99.97	6168	99.9
Biobank	Overall	PALB2	11	0.11	3	0.35	3.12 (0.87 to 11.2)	0.081
		POLK	29	0.30	2	0.23	0.78 (0.19 to 3.29)	0.74
		Non-carrier	9685	99.6	853	99.4
	HGSOC†	PALB2	11	0.11	1	0.28	2.49 (0.32 to 19.4)	0.38
		POLK	29	0.30	1	0.28	0.92 (0.12 to 6.74)	0.93
		Non-carrier	9685	99.6	361	99.4

*OCAC: OCAC sample genotype on the OncoArray; Biobank: genotype from UK Biobank Axiom Array.

†Information on tumour grade was not available for UK Biobank cases, all the serous cases in UK Biobank were assumed to be HGSOC.

EOC, epithelial ovarian cancer.